Oral Liquid 13-cis-retinoic Acid (13-CRA)

Summary

An open label, randomised, multiple dose, cross-over relative bioavailability and pharmacokinetics trial of a novel oral liquid and capsule formulations of 13-CRA administered to patients from 0 months - \< 21 years.

Timeline

Start

2018-04-17

Primary completion

2019-09-12

Completion

2019-09-12

Publications

• Veal GJ, Tweddle DA, Visser J, Errington J, Buck H, Marange J, Moss J, Joseph S, Mulla H. Pharmacokinetics and Safety of a Novel Oral Liquid Formulation of 13-cis Retinoic Acid in Children with Neuroblastoma: A Randomized Crossover Clinical Trial. Cancers (Basel). 2021 Apr 14;13(8):1868. doi: 10.3390/cancers13081868.

Drugs

Indications